Daiichi Sankyō (4568.T) Financial Analysis & Valuation | Quarter Chart
Daiichi Sankyō (4568.T)
4568.TPrice: $17.03
Fair Value: 🔒
🔒score
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for... more
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells p... more
Description
Shares
| Market Cap | $31.00B | Exchange | JPX |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | JP | CEO | Hiroyuki Okuzawa |
| IPO Date | 2000-01-04 | CAGR | 0.05% |
| Employees | 18,726 | Website | www.daiichisankyo.com |
| Div. Yield | 2.88% | Payout Ratio | 0.49% |
| Buy Back Yield | 3.06% | Total Yield | 5.94% |
4568.T chart loading...
Fundamentals
Technicals
| Enterprise Value | $4930.57B | P/E Ratio | 19.27 |
| Forward P/E | — | PEG Ratio | -0.38 |
| P/S Ratio | 2.32 | P/B Ratio | 2.99 |
| P/CF Ratio | 64 | P/FCF Ratio | -97.1 |
| EPS | $0.88 | EPS Growth 1Y | -9.93% |
| EPS Growth 3Y | 146.56% | EPS Growth 5Y | 259.68% |
| Revenue Growth 1Y | 12.55% | Gross Margin | 0.68% |
| Operating Margin | 0.1% | Profit Margin | 0.12% |
| ROE | 0.16% | ROA | 0.06% |
| ROCE | 0.07% | Current Ratio | 2.42 |
| Quick Ratio | 1.64 | Cash Ratio | 0.51 |
| Debt/Equity | 0.18 | Interest Coverage | 26.05 |
| Altman Z Score | 2.88 | Piotroski Score | 5 |